The impact of (18)F-FDG-PET/CT on Merkel cell carcinoma management: a retrospective study of 66 scans from a single institution
| Autor: | Adeline George, Remy Delva, Aude Testard, Olivier Morel, Olivier-F. Couturier, Sylvie Girault, Patrick Soulié |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
medicine.medical_specialty Skin Neoplasms Multimodal Imaging Fluorodeoxyglucose F18 Recurrence Positive predicative value medicine Carcinoma Humans Radiology Nuclear Medicine and imaging Lymph node Aged Neoplasm Staging Retrospective Studies Aged 80 and over medicine.diagnostic_test business.industry Merkel cell carcinoma Retrospective cohort study General Medicine medicine.disease Surgery Carcinoma Merkel Cell medicine.anatomical_structure Positron emission tomography Positron-Emission Tomography Female Tomography Radiology business Merkel cell Tomography X-Ray Computed Follow-Up Studies |
| Zdroj: | Nuclear medicine communications. 35(3) |
| ISSN: | 1473-5628 |
| Popis: | Purpose Merkel cell carcinomas (MCC) are neuroendocrine skin tumours frequently responsible for lymph node recurrence and metastatic disease and for which optimal management remains to be defined. The objective of this study was to evaluate the impact of (18)F-fluorodeoxyglucose ((18)F-FDG)-PET/computed tomography (CT) on the staging and treatment of MCC patients. Materials and methods Twenty-three patients with a histologic diagnosis of MCC explored by (18)F-FDG-PET/CT between 2004 and 2012 were retrospectively included in the study. The detection of new lesions and the change in tumour staging and treatment were evaluated. For each patient, the (18)F-FDG-PET/CT results were compared with histological, clinical and imaging data. Results Sixty-six (18)F-FDG-PET/CT scans were performed at initial presentation (n=18), during subsequent monitoring (n=34) or during evaluation of chemotherapy response (n=14). The sensitivity, specificity and positive and negative predictive values of the (18)F-FDG-PET/CT were 97, 89, 94 and 94%, respectively. Two false-positive results (lymphadenitis) and one false-negative result (regional metastatic lymph nodes) were accounted for. Lesions not detected clinically or by conventional imaging techniques were found in 44% of the 52 (18)F-FDG-PET/CTs performed at initial presentation and subsequent monitoring, with, respectively, 50 and 41% of scans identifying new lesions. At initial presentation, (18)F-FDG-PET/CT led to a change in tumour staging in 39% of patients. Patient management was modified by (18)F-FDG-PET/CT results in one-third of patients (33% of patients at initial presentation, 32% during subsequent monitoring and 36% during evaluation of chemotherapy response). F-FDG-PET/CT incidentally detected four additional histologically confirmed cancers. Conclusion This retrospective study confirms the important impact of (18)F-FDG-PET/CT on the management of MCC patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|